

MAY 27TH 2011 - PHARMASCIENCE ACQUIRES AEGERA THERAPEUTICS

Pharmascience, the largest generic pharmaceutical company in Quebec, Canada is pleased to announce the acquisition of Aegera Therapeutics Inc., a Montreal-based clinical-stage biotechnology company focused on developing targeted therapeutics to address unmet major medical needs, primarily in oncology.

Pharmascience, which ranks 52nd among Canada's largest R&D investors in all activity sectors combined, consistently aims to ensure that R&D remains targeted to meet global and regional demands. Over the last ten years, Pharmascience has initiated major expansion projects estimated at over \$50 million in order to meet growing global demand. Scientific activities occupy more than 30% of the company's human resources. The goals of Pharmascience's R&D activities are to develop generic drugs that meet Canadian and International standards/criteria for bioequivalence and bioavailability and to identify new therapeutic uses and delivery systems for drugs already developed to treat specific illnesses.

"The acquisition of Aegera will enable Pharmascience to increase and diversify its research and development activities" stated David Goodman, Chief Executive Officer of Pharmascience, "This acquisition will strengthen Pharmascience's position as a pharmaceutical leader, and will solidify our organization's diversification and international expansion strategy."

To learn more about Aegera Therapeutics Inc. please visit their website by clicking [here](#).